January I, 2024

The sequencing of treatments for neuroendocrine tumors lacks robust clinical trials to serve as guideposts because of the heterogeneity of the tumors and their rare incidence.

The latest advances regarding local and systemic regulatory mechanisms of immune responses in cold and hot tumors will be an important topic explored during the 9th Annual School of Gastrointestinal Oncology.

Three-year data showed durable clinical activity with nadofaragene firadenovec-vncg in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.

In the phase 3 BOND-003 trial, cretostimogene grenadenorepvec led to complete responses in over three-fourths of patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer.

Research is ongoing to identify biomarkers in hepatocellular carcinoma that are predictive in nature, according to Richard Kim, MD.

If the title is correct, an article in the November 10 issue of the Journal of Clinical Oncology shows that many randomized trials in oncology are improperly designed and many drugs used in oncology have been approved based on the wrong end point.